Consistent with this finding in GBM, the loss of the PPP2R2C subunit was associated with an increase in prostate cancer cell proliferation, particularly in resistant cases to androgen ligand depletion, suggesting that PPP2R2C plays a suppressive role in GBM and prostate carcinogenesis, indicating its potential as a therapeutic target in the management of these diseases [10]. Here, PPP2R2C is linked to prostate cancer.